Practice
Featured experience
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
InVue sale to ASSA ABLOY
We advised InVue on the transaction
Ferrero Group acquisition of Power Crunch
We are advising Ferrero on the transaction
ASMedia Technology $390 million acquisition of Techpoint
We are advising ASMedia on the transaction
Trustar Capital participation in proposed acquisition of Energy Monster
We advised Trustar Capital as a consortium member
Rokt $300 million merger with mParticle
We are advising Rokt on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Big Lots sale of substantially all of its assets to Gordon Brothers Retail Partners
We advised Big Lots on the sale
Cintas $5.3 billion proposal to acquire UniFirst
We are advising Cintas on the proposed acquisition